BioTime, Inc. today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the sale of BioTime common shares. BioTime and the subsidiaries intend to use the net proceeds from their sales to finance clinical trials of products under development, to finance their research and development programs, and for general working capital.
http://ift.tt/1w1zLHq
http://ift.tt/1w1zLHq
No comments:
Post a Comment